Six-month and One-year Outcomes for Repair in Patients with Functional Mitral Regurgitation from the CLASP Study

Abstract

Background Transcatheter mitral valve repair has emerged as a viable option for treating functional mitral regurgitation (FMR). We report results for the FMR cohort from the multicenter, prospective, single arm CLASP study with the PASCAL transcatheter valve repair system (Edwards Lifesciences, Irvine, CA). Methods Eligible patients had clinically significant and symptomatic MR ≥3+ and were deemed candidates for transcatheter repair by the local heart team. The study outcomes were evaluated by an independent clinical events committee and echocardiographic core lab. The primary safety endpoint was a composite MAE rate at 30 days of cardiovascular mortality, stroke, MI, new need for renal replacement therapy, severe bleeding, and re-intervention for study device-related complications. Results Of the 109 patients enrolled (intent to treat/ITT and roll-in), 73 (67%) had FMR as determined by the core lab. Mean age was 73 years, 55% male, 60% NYHA Class III/IV with 100% MR grade ≥3+. Successful implantation was achieved in 96% of patients. At 30 days, the MAE rate was 11.0% including one cardiovascular mortality, one stroke, and one conversion to mitral valve replacement surgery. At 30 days, 88% of patients were in NYHA Class I/II (p Conclusions This study demonstrates that the PASCAL repair system is safe and results in remarkable MR reduction in patients with FMR. 100% of patients achieved MR ≤2+, and ∼ 80% achieved MR ≤1+, sustained at one year. Results show a high survival rate, low complications, and sustained improvements in functional status, exercise capacity, and quality of life at one year.